Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pregabalin: a new anxiolytic.

Bianca A Lauria-Horner1, Robert B Pohl

  • 1Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.

Expert Opinion on Investigational Drugs
|April 1, 2003
PubMed
Summary

Pregabalin, a GABA analogue, shows potent anticonvulsant and anxiolytic effects by modulating calcium channels. It is well-tolerated and effective for anxiety disorders, with rapid absorption and high bioavailability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.

Journal of clinical psychopharmacology·2005
Same author

The feasibility of a mental health curriculum in elementary school.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2004
Same author

Diminished chaos of heart rate time series in patients with major depression.

Biological psychiatry·2002
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Pregabalin is a lipophilic gamma-aminobutyric acid (GABA) analogue designed for blood-brain barrier penetration.
  • Originally developed as an anticonvulsant, it also shows efficacy in treating hyperalgesia and behavioral disorders.

Purpose of the Study:

  • To elucidate the pharmacological profile and therapeutic potential of pregabalin.
  • To evaluate its efficacy and tolerability in various neurological and psychiatric conditions.

Main Methods:

  • Preclinical studies assessing anticonvulsant activity and animal models of anxiety.
  • Pharmacokinetic analysis in healthy volunteers.
  • Phase II and III clinical trials for generalized anxiety disorder, social phobia, and panic disorder.

Main Results:

  • Pregabalin is 3-10 times more potent than gabapentin in preclinical anticonvulsant trials.
  • Rapid absorption (peak concentration within 1h) and high bioavailability (~90%) observed.
  • Demonstrated promising anxiolytic effects compared to placebo in Phase II/III trials for anxiety disorders.

Conclusions:

  • Pregabalin effectively modulates voltage-dependent calcium channels, impacting neuronal excitability.
  • It is well-tolerated with mild, transient side effects and no reported pharmacokinetic drug-drug interactions.
  • Pregabalin presents a promising therapeutic option for anxiety disorders and potentially other neurological conditions.

Related Experiment Videos